PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 69 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,333,977 | +38.0% | 122,271 | 0.0% | 0.05% | +31.6% |
| Q2 2022 | $967,000 | -66.6% | 122,271 | 0.0% | 0.04% | -62.7% |
| Q1 2022 | $2,895,000 | -16.2% | 122,271 | +21.0% | 0.10% | -8.1% |
| Q4 2021 | $3,455,000 | +126.1% | 101,037 | +17.2% | 0.11% | +126.5% |
| Q3 2021 | $1,528,000 | +4.0% | 86,237 | -28.9% | 0.05% | -18.3% |
| Q2 2019 | $1,469,000 | -34.1% | 121,341 | -31.6% | 0.06% | -34.1% |
| Q1 2019 | $2,230,000 | +68.0% | 177,425 | -10.0% | 0.09% | +59.6% |
| Q4 2018 | $1,327,000 | -41.1% | 197,138 | -10.0% | 0.06% | -30.5% |
| Q3 2018 | $2,254,000 | +53.1% | 219,042 | 0.0% | 0.08% | +46.4% |
| Q2 2018 | $1,472,000 | -21.8% | 219,042 | 0.0% | 0.06% | -23.3% |
| Q1 2018 | $1,882,000 | +9.2% | 219,042 | +164.5% | 0.07% | +10.6% |
| Q4 2017 | $1,723,000 | +1148.6% | 82,822 | +958.8% | 0.07% | +1220.0% |
| Q3 2017 | $138,000 | – | 7,822 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $43,400,000 | 3.81% |
| BVF INC/IL | 3,901,759 | $69,139,000 | 2.70% |
| COMMODORE CAPITAL LP | 498,079 | $8,826,000 | 2.33% |
| Altium Capital Management LP | 346,000 | $6,131,000 | 1.61% |
| Twin Lakes Capital Management, LLC | 139,287 | $2,468,000 | 1.45% |
| Opaleye Management Inc. | 330,222 | $5,852,000 | 1.09% |
| EcoR1 Capital, LLC | 1,443,800 | $25,584,000 | 0.89% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 776,689 | $13,763,000 | 0.76% |
| JABODON PT CO | 90,656 | $1,606,000 | 0.66% |
| Artal Group S.A. | 1,500,000 | $26,580,000 | 0.60% |